The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive whole-genome analysis of colorectal cancer (CONDUCTOR study): Integrating RAS/BRAF, MSI status, and intron–exon alterations.
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Koji Ando
Honoraria - Merck
 
Yusuke Suwa
No Relationships to Disclose
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Yoshinori Kagawa
Consulting or Advisory Role - Lilly; Merck; Taiho Pharmaceutical; Takeda Science Foundation
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Mamoru Uemura
No Relationships to Disclose
 
Tadayoshi Hashimoto
Honoraria - Cytogen; Takata Pharmaceutical
 
Naomi Kuramoto
No Relationships to Disclose
 
Takao Fujisawa
Honoraria - Amelief; AstraZeneca; Merck Serono
 
Yuichi Shiraishi
No Relationships to Disclose
 
Saori Mishima
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Consulting or Advisory Role - Exact Sciences
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Guardant Health; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - MSD K.K; Seagen; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); Daiichi Sankyo/UCB Japan (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Riu Yamashita
Consulting or Advisory Role - Takeda
 
Shingo Sakashita
No Relationships to Disclose
 
Takeshi Kuwata
Honoraria - Agilent; Astellas Pharma; Bristol-Myers Squibb Japan; Daiichi Sankyo; FALCO biosystems; Guardant Health; MSD; Myriad Genetics; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; Daiichi Sankyo; GxD; Roche
Research Funding - Takeda (Inst)
 
Toru Mukohara
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Kirin; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Eisai; Micin; Pfizer
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Gilead Sciences (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst)
 
Yoichi Naito
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Gilead Sciences; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; FUJIFILM Toyama Chemistry; Gilead Sciences; Guardant Health; Hisamitsu Pharmaceutical; Lilly; MSD; Mundipharma; Novartis; Ono Yakuhin; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; AstraZeneca Japan; Boehringer Ingelheim; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
 
Jun Watanabe
Honoraria - Covidien; Johnson & Johnson/MedTech; Lilly; Takeda; TERUMO
Research Funding - Covidien (Inst); Stryker (Inst); TERUMO (Inst)
 
Kuniko Sunami
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Guardant Health; Illumina; Konica Minolta Precision Medicine; Lilly; Novartis; Pfizer; Riken Genesis; Sysmex
Research Funding - Sysmex
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)